Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Denali Therapeutics Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Denali Therapeutics held its annual stockholder meeting on June 3, 2026, where three Class III directors were elected to serve until 2029, with 87% shareholder participation demonstrating strong governance engagement.
Key Takeaways
Three Class III directors were elected at the annual meeting to serve three-year terms through 2029
137.9 million of 158.7 million outstanding shares were represented, indicating 87% shareholder participation
2 more takeaways